Author/Authors :
Li, Yanfei Department of Radiology - Xiang’an Hospital of Xiamen University - Xiamen, China , Ren, Ke Department of Radiology - Xiang’an Hospital of Xiamen University - Xiamen, China
Abstract :
Contrast-induced acute kidney injury (CI-AKI) is the third most common hospital-acquired AKI after AKI induced by renal
perfusion insufficiency and nephrotoxic drugs, taking great adverse effects on the prognosis and increasing hospital stay and
medical cost. Diabetes nephropathy (DN) is a common chronic complication of DM (diabetes mellitus), and DN is an independent risk factor for chronic kidney disease (CKD) and CI-AKI. -e incidence of CI-AKI significantly increases in patients with
renal injury, especially in DM-related nephropathy. The etiology of CI-AKI is not fully clear, and research studies on how DM
becomes a facilitated factor of CI-AKI are limited. This review describes the mechanism from three aspects. ① Pathophysiological
changes of CI-AKI in kidney under high-glucose status (HGS). HGS can enhance the oxidative stress and increase ROS which next
causes stronger vessel constriction and insufficient oxygen supply in kidney via vasoactive substances. HGS also aggravates some
ion pump load and the latter increases oxygen consumption. CI-AKI and HGS are mutually causal, making the kidney function
continue to decline. ② Immunological changes of DM promoting CI-AKI. Some innate immune cells and pattern recognition
receptors (PRRs) in DM and/or DN may respond to some damage-associated molecular patterns (DAMPs) formed by CI-AKI.
These effects overlap with some pathophysiological changes in hyperglycemia. ③ Signaling pathways related to both CI-AKI and
DM. These pathways involved in CI-AKI are closely associated with apoptosis, inflammation, and ROS production, and some
studies suggest that these pathways may be potential targets for alleviating CI-AKI. In conclusion, the pathogenesis of CI-AKI and
the mechanism of DM as a predisposing factor for CI-AKI, especially signaling pathways, need further investigation to provide
new clinical approaches to prevent and treat CI-AKI.